Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,31050868,Total,"Total and unbound dabigatran levels at baseline were 165 ng/mL vs 110 ng/mL and 103 ng/mL vs 69.5 ng/mL in group A and B patients, respectively.",Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31050868/),[ng] / [ml],165,4339,DB06695,Dabigatran etexilate
,31050868,Total,"Total and unbound dabigatran levels at baseline were 165 ng/mL vs 110 ng/mL and 103 ng/mL vs 69.5 ng/mL in group A and B patients, respectively.",Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31050868/),[ng] / [ml],110,4340,DB06695,Dabigatran etexilate
,31050868,Total,"Total and unbound dabigatran levels at baseline were 165 ng/mL vs 110 ng/mL and 103 ng/mL vs 69.5 ng/mL in group A and B patients, respectively.",Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31050868/),[ng] / [ml],103,4341,DB06695,Dabigatran etexilate
,31050868,unbound,"Total and unbound dabigatran levels at baseline were 165 ng/mL vs 110 ng/mL and 103 ng/mL vs 69.5 ng/mL in group A and B patients, respectively.",Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31050868/),[ng] / [ml],165,4342,DB06695,Dabigatran etexilate
,31050868,unbound,"Total and unbound dabigatran levels at baseline were 165 ng/mL vs 110 ng/mL and 103 ng/mL vs 69.5 ng/mL in group A and B patients, respectively.",Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31050868/),[ng] / [ml],110,4343,DB06695,Dabigatran etexilate
,31050868,unbound,"Total and unbound dabigatran levels at baseline were 165 ng/mL vs 110 ng/mL and 103 ng/mL vs 69.5 ng/mL in group A and B patients, respectively.",Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31050868/),[ng] / [ml],103,4344,DB06695,Dabigatran etexilate
,31050868,unbound,"Total and unbound dabigatran levels at baseline were 165 ng/mL vs 110 ng/mL and 103 ng/mL vs 69.5 ng/mL in group A and B patients, respectively.",Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31050868/),[ng] / [ml],69.5,4345,DB06695,Dabigatran etexilate
,31050868,levels,"Total and unbound dabigatran levels at baseline were 165 ng/mL vs 110 ng/mL and 103 ng/mL vs 69.5 ng/mL in group A and B patients, respectively.",Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31050868/),[ng] / [ml],103,4346,DB06695,Dabigatran etexilate
,31050868,levels,"Total and unbound dabigatran levels at baseline were 165 ng/mL vs 110 ng/mL and 103 ng/mL vs 69.5 ng/mL in group A and B patients, respectively.",Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31050868/),[ng] / [ml],69.5,4347,DB06695,Dabigatran etexilate
,31050868,Maximum plasma concentrations,"Maximum plasma concentrations and area under the curves (AUC0-24 ) of idarucizumab in group A vs B, respectively, were 24 900 nmol/L vs 25 000 nmol/L and 76 600 nmol/h/L vs 68 000 nmol/h/L.",Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31050868/),[nM] / [l],24 900,4348,DB06695,Dabigatran etexilate
,31050868,Maximum plasma concentrations,"Maximum plasma concentrations and area under the curves (AUC0-24 ) of idarucizumab in group A vs B, respectively, were 24 900 nmol/L vs 25 000 nmol/L and 76 600 nmol/h/L vs 68 000 nmol/h/L.",Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31050868/),[nM] / [l],25 000,4349,DB06695,Dabigatran etexilate
,31050868,area under the curves (AUC0-24 ),"Maximum plasma concentrations and area under the curves (AUC0-24 ) of idarucizumab in group A vs B, respectively, were 24 900 nmol/L vs 25 000 nmol/L and 76 600 nmol/h/L vs 68 000 nmol/h/L.",Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31050868/),[nM] / [h·l],76 600,4350,DB06695,Dabigatran etexilate
,31050868,area under the curves (AUC0-24 ),"Maximum plasma concentrations and area under the curves (AUC0-24 ) of idarucizumab in group A vs B, respectively, were 24 900 nmol/L vs 25 000 nmol/L and 76 600 nmol/h/L vs 68 000 nmol/h/L.",Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31050868/),[nM] / [h·l],68 000,4351,DB06695,Dabigatran etexilate
<,31050868,unbound,Idarucizumab immediately decreased unbound dabigatran concentration (<20 ng/mL).,Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31050868/),[ng] / [ml],20,4352,DB06695,Dabigatran etexilate
,23535530,half-life,"Apixaban has a half-life of about 12 hours, and the normal dosage is 5 mg orally twice daily.",Apixaban: a new factor Xa inhibitor for stroke prevention in patients with nonvalvular atrial fibrillation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23535530/),h,12,8513,DB06695,Dabigatran etexilate
,20551237,apparent half-life,"The 1-O-acylglucuronide, in addition to minor hydrolysis to the aglycon, underwent nonenzymatic acyl migration in aqueous solution, resulting in the formation of the 2-O-, 3-O-, and 4-O-acylglucuronides with an apparent half-life of 1 h (37 degrees C, pH 7.4).","Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20551237/),h,1,15724,DB06695,Dabigatran etexilate
,20551237,K(m),"The glucuronidation of dabigatran was catalyzed by human hepatic and intestinal microsomes with K(m) values in the range of 180 to 255 and 411 to 759 microM, respectively.","Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20551237/),μM,180 to 255,15725,DB06695,Dabigatran etexilate
,20551237,K(m),"The glucuronidation of dabigatran was catalyzed by human hepatic and intestinal microsomes with K(m) values in the range of 180 to 255 and 411 to 759 microM, respectively.","Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20551237/),μM,411 to 759,15726,DB06695,Dabigatran etexilate
,30411284,Elimination half-lives,Elimination half-lives could be estimated in eight patients and ranged between 14.6 and 59.7 h (median 21.6).,Serum Concentrations and Elimination Rates of Direct-Acting Oral Anticoagulants (DOACs) in Older Hip Fracture Patients Hospitalized for Surgery: A Pilot Study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30411284/),h,21.6,22073,DB06695,Dabigatran etexilate
,30411284,waiting time for,The observed waiting time for surgery was longer for patients using DOACs than warfarin (median 44 vs. 25 h).,Serum Concentrations and Elimination Rates of Direct-Acting Oral Anticoagulants (DOACs) in Older Hip Fracture Patients Hospitalized for Surgery: A Pilot Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30411284/),h,44,22074,DB06695,Dabigatran etexilate
,30411284,waiting time for,The observed waiting time for surgery was longer for patients using DOACs than warfarin (median 44 vs. 25 h).,Serum Concentrations and Elimination Rates of Direct-Acting Oral Anticoagulants (DOACs) in Older Hip Fracture Patients Hospitalized for Surgery: A Pilot Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30411284/),h,25,22075,DB06695,Dabigatran etexilate
,31652461,Cmax,"The dabigatran etexilate mean Cmax was 6.9±5.63 ng/mL, the median Tmax was 0.67 h (range=0.50-1.00 h), the mean AUCt was 5.32±4.82 ng/mL·h, the mean AUCinf was 5.36±4.83 pg/mL*h, and the mean t1/2 was 0.54±0.26 h.","A Pharmacokinetic Evaluation of Dabigatran Etexilate, Total Dabigatran, and Unconjugated Dabigatran Following the Administration of Dabigatran Etexilate Mesylate Capsules in Healthy Male and Female Subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31652461/),[ng] / [ml],6.9,24622,DB06695,Dabigatran etexilate
,31652461,Tmax,"The dabigatran etexilate mean Cmax was 6.9±5.63 ng/mL, the median Tmax was 0.67 h (range=0.50-1.00 h), the mean AUCt was 5.32±4.82 ng/mL·h, the mean AUCinf was 5.36±4.83 pg/mL*h, and the mean t1/2 was 0.54±0.26 h.","A Pharmacokinetic Evaluation of Dabigatran Etexilate, Total Dabigatran, and Unconjugated Dabigatran Following the Administration of Dabigatran Etexilate Mesylate Capsules in Healthy Male and Female Subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31652461/),h,0.67,24623,DB06695,Dabigatran etexilate
,31652461,AUCt,"The dabigatran etexilate mean Cmax was 6.9±5.63 ng/mL, the median Tmax was 0.67 h (range=0.50-1.00 h), the mean AUCt was 5.32±4.82 ng/mL·h, the mean AUCinf was 5.36±4.83 pg/mL*h, and the mean t1/2 was 0.54±0.26 h.","A Pharmacokinetic Evaluation of Dabigatran Etexilate, Total Dabigatran, and Unconjugated Dabigatran Following the Administration of Dabigatran Etexilate Mesylate Capsules in Healthy Male and Female Subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31652461/),[ng] / [h·ml],5.32,24624,DB06695,Dabigatran etexilate
,31652461,AUCinf,"The dabigatran etexilate mean Cmax was 6.9±5.63 ng/mL, the median Tmax was 0.67 h (range=0.50-1.00 h), the mean AUCt was 5.32±4.82 ng/mL·h, the mean AUCinf was 5.36±4.83 pg/mL*h, and the mean t1/2 was 0.54±0.26 h.","A Pharmacokinetic Evaluation of Dabigatran Etexilate, Total Dabigatran, and Unconjugated Dabigatran Following the Administration of Dabigatran Etexilate Mesylate Capsules in Healthy Male and Female Subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31652461/),[pg] / [h·ml],5.36,24625,DB06695,Dabigatran etexilate
,31652461,t1/2,"The dabigatran etexilate mean Cmax was 6.9±5.63 ng/mL, the median Tmax was 0.67 h (range=0.50-1.00 h), the mean AUCt was 5.32±4.82 ng/mL·h, the mean AUCinf was 5.36±4.83 pg/mL*h, and the mean t1/2 was 0.54±0.26 h.","A Pharmacokinetic Evaluation of Dabigatran Etexilate, Total Dabigatran, and Unconjugated Dabigatran Following the Administration of Dabigatran Etexilate Mesylate Capsules in Healthy Male and Female Subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31652461/),h,0.54,24626,DB06695,Dabigatran etexilate
,27496339,max,The dabigatran concentration between 2 and 9 hr after administration was higher in SRF than in vitreous (max 8.5 and 3.8 ng/ml).,Vitreous and subretinal fluid concentrations of orally administered dabigatran in patients with rhegmatogenous retinal detachment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27496339/),[ng] / [ml],8.5,24713,DB06695,Dabigatran etexilate
,27496339,max,The dabigatran concentration between 2 and 9 hr after administration was higher in SRF than in vitreous (max 8.5 and 3.8 ng/ml).,Vitreous and subretinal fluid concentrations of orally administered dabigatran in patients with rhegmatogenous retinal detachment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27496339/),[ng] / [ml],3.8,24714,DB06695,Dabigatran etexilate
,31167814,IC50,"Glecaprevir inhibited P-gp, BCRP, OATP1B1, and OATP1B3 with IC50 values of 0.33, 2.3, 0.017, and 0.064 µM, respectively.",Translation of In Vitro Transport Inhibition Studies to Clinical Drug-Drug Interactions for Glecaprevir and Pibrentasvir. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31167814/),μM,0.33,24850,DB06695,Dabigatran etexilate
,31167814,IC50,"Glecaprevir inhibited P-gp, BCRP, OATP1B1, and OATP1B3 with IC50 values of 0.33, 2.3, 0.017, and 0.064 µM, respectively.",Translation of In Vitro Transport Inhibition Studies to Clinical Drug-Drug Interactions for Glecaprevir and Pibrentasvir. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31167814/),μM,2.3,24851,DB06695,Dabigatran etexilate
,31167814,IC50,"Glecaprevir inhibited P-gp, BCRP, OATP1B1, and OATP1B3 with IC50 values of 0.33, 2.3, 0.017, and 0.064 µM, respectively.",Translation of In Vitro Transport Inhibition Studies to Clinical Drug-Drug Interactions for Glecaprevir and Pibrentasvir. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31167814/),μM,0.017,24852,DB06695,Dabigatran etexilate
,31167814,IC50,"Glecaprevir inhibited P-gp, BCRP, OATP1B1, and OATP1B3 with IC50 values of 0.33, 2.3, 0.017, and 0.064 µM, respectively.",Translation of In Vitro Transport Inhibition Studies to Clinical Drug-Drug Interactions for Glecaprevir and Pibrentasvir. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31167814/),μM,0.064,24853,DB06695,Dabigatran etexilate
,31167814,IC50,"Pibrentasvir inhibited P-gp, BCRP, and OATP1B1 with IC50 values of 0.036, 14, and 1.3 µM, respectively.",Translation of In Vitro Transport Inhibition Studies to Clinical Drug-Drug Interactions for Glecaprevir and Pibrentasvir. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31167814/),μM,0.036,24854,DB06695,Dabigatran etexilate
,31167814,IC50,"Pibrentasvir inhibited P-gp, BCRP, and OATP1B1 with IC50 values of 0.036, 14, and 1.3 µM, respectively.",Translation of In Vitro Transport Inhibition Studies to Clinical Drug-Drug Interactions for Glecaprevir and Pibrentasvir. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31167814/),μM,14,24855,DB06695,Dabigatran etexilate
,31167814,IC50,"Pibrentasvir inhibited P-gp, BCRP, and OATP1B1 with IC50 values of 0.036, 14, and 1.3 µM, respectively.",Translation of In Vitro Transport Inhibition Studies to Clinical Drug-Drug Interactions for Glecaprevir and Pibrentasvir. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31167814/),μM,1.3,24856,DB06695,Dabigatran etexilate
,25661675,plasma elimination half-life,"The plasma elimination half-life of dabigatran was 1.5-4.9 h during IHD, and 14.0-27.5 h during CRRT.",Comparison of intermittent and continuous extracorporeal treatments for the enhanced elimination of dabigatran. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25661675/),h,1.5-4.9,36723,DB06695,Dabigatran etexilate
,25661675,plasma elimination half-life,"The plasma elimination half-life of dabigatran was 1.5-4.9 h during IHD, and 14.0-27.5 h during CRRT.",Comparison of intermittent and continuous extracorporeal treatments for the enhanced elimination of dabigatran. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25661675/),h,14.0-27.5,36724,DB06695,Dabigatran etexilate
,25661675,plasma clearance,Mean dabigatran plasma clearance during IHD was 85-169 mL/min in three patients.,Comparison of intermittent and continuous extracorporeal treatments for the enhanced elimination of dabigatran. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25661675/),[ml] / [min],85-169,36725,DB06695,Dabigatran etexilate
,25661675,Time to obtain,"Time to obtain a subtherapeutic dabigatran concentration depended on the initial concentration, being 8-18 h for IHD in three patients while 4 h was insufficient in a supratherapeutic case.",Comparison of intermittent and continuous extracorporeal treatments for the enhanced elimination of dabigatran. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25661675/),h,8-18,36726,DB06695,Dabigatran etexilate
,25661675,Time to obtain,"Time to obtain a subtherapeutic dabigatran concentration depended on the initial concentration, being 8-18 h for IHD in three patients while 4 h was insufficient in a supratherapeutic case.",Comparison of intermittent and continuous extracorporeal treatments for the enhanced elimination of dabigatran. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25661675/),h,4,36727,DB06695,Dabigatran etexilate
,18006647,bioavailability,"Dabigatran etexilate was rapidly converted to dabigatran, with peak plasma dabigatran concentrations being attained after approximately 1.5 h; the bioavailability of dabigatran after p.o. administration of dabigatran etexilate was 7.2%.","The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18006647/),%,7.2,42385,DB06695,Dabigatran etexilate
,18006647,terminal half-life,The mean terminal half-life of dabigatran was approximately 8 h.,"The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18006647/),h,8,42386,DB06695,Dabigatran etexilate
,29291414,maximum plasma concentration,"In 5-FU-treated rats, the maximum plasma concentration, the area under the concentration-time curve of DAB after the oral administration of DABE, and the oral bioavailability of DABE were significantly decreased to 18.3%, 22.9%, and 16.3% of the respective control values.",5-Fluororacil-Induced Gastrointestinal Damage Impairs the Absorption and Anticoagulant Effects of Dabigatran Etexilate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29291414/),%,18.3,44416,DB06695,Dabigatran etexilate
,29291414,area under the concentration-time curve,"In 5-FU-treated rats, the maximum plasma concentration, the area under the concentration-time curve of DAB after the oral administration of DABE, and the oral bioavailability of DABE were significantly decreased to 18.3%, 22.9%, and 16.3% of the respective control values.",5-Fluororacil-Induced Gastrointestinal Damage Impairs the Absorption and Anticoagulant Effects of Dabigatran Etexilate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29291414/),%,22.9,44417,DB06695,Dabigatran etexilate
,29291414,area under the concentration-time curve,"In 5-FU-treated rats, the maximum plasma concentration, the area under the concentration-time curve of DAB after the oral administration of DABE, and the oral bioavailability of DABE were significantly decreased to 18.3%, 22.9%, and 16.3% of the respective control values.",5-Fluororacil-Induced Gastrointestinal Damage Impairs the Absorption and Anticoagulant Effects of Dabigatran Etexilate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29291414/),%,16.3,44418,DB06695,Dabigatran etexilate
,29291414,oral bioavailability,"In 5-FU-treated rats, the maximum plasma concentration, the area under the concentration-time curve of DAB after the oral administration of DABE, and the oral bioavailability of DABE were significantly decreased to 18.3%, 22.9%, and 16.3% of the respective control values.",5-Fluororacil-Induced Gastrointestinal Damage Impairs the Absorption and Anticoagulant Effects of Dabigatran Etexilate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29291414/),%,16.3,44419,DB06695,Dabigatran etexilate
,20214409,terminal elimination half-life,"In subjects with severe renal impairment, the mean terminal elimination half-life was doubled (28 hours vs 14 hours for control).","Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20214409/),h,28,48053,DB06695,Dabigatran etexilate
,20214409,terminal elimination half-life,"In subjects with severe renal impairment, the mean terminal elimination half-life was doubled (28 hours vs 14 hours for control).","Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20214409/),h,14,48054,DB06695,Dabigatran etexilate
,27352238,trough,"Geometric mean trough and peak dabigatran concentrations were 47.5ng/mL (10th-90th percentile 19.7-120) and 166ng/mL (49.1-364), respectively.",An open-label study of the pharmacokinetics and pharmacodynamics of dabigatran etexilate 150mg once daily in Caucasian patients with moderate renal impairment undergoing primary unilateral elective total knee or hip replacement surgery. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27352238/),[ng] / [ml],47.5,48168,DB06695,Dabigatran etexilate
,27352238,peak dabigatran concentrations,"Geometric mean trough and peak dabigatran concentrations were 47.5ng/mL (10th-90th percentile 19.7-120) and 166ng/mL (49.1-364), respectively.",An open-label study of the pharmacokinetics and pharmacodynamics of dabigatran etexilate 150mg once daily in Caucasian patients with moderate renal impairment undergoing primary unilateral elective total knee or hip replacement surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27352238/),[ng] / [ml],166,48169,DB06695,Dabigatran etexilate
higher,25797721,recoveries,"The recoveries were higher than 89.48%, the accuracy was within 98.33-110.12% and the RSD was below 10% for the studied compounds in both incurred plasma and quality control samples.",Development and validation of LC-MSMS assay for the determination of the prodrug dabigatran etexilate and its active metabolites in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25797721/),%,89.48,49761,DB06695,Dabigatran etexilate
,24666338,activated partial th,"Eleven hours post overdose extracorporeal elimination was implemented as the patient developed worsening coagulopathy with an elevated international normalized ratio of 11 IU, an activated partial thromboplastin time of 115 s, and had renal impairment with a creatinine of 158 μmol/L.",Use of continuous veno-venous haemodiafiltration therapy in dabigatran overdose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24666338/),s,115,53236,DB06695,Dabigatran etexilate
,24666338,peak serum dabigatran level,"This patient developed a peak serum dabigatran level of 1560 ng/ml, 11 h postoverdose.",Use of continuous veno-venous haemodiafiltration therapy in dabigatran overdose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24666338/),[ng] / [ml],1560,53237,DB06695,Dabigatran etexilate
,24666338,clearance,"Clearance of dabigatran via continuous veno-venous hemodiafiltration was calculated, using both the recovery and A-V pair methods, with a mean clearance of 58.1 and 31.9 ml/h, respectively, and a calculated mean extraction ratio of 0.2.",Use of continuous veno-venous haemodiafiltration therapy in dabigatran overdose. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24666338/),[ml] / [h],58.1,53238,DB06695,Dabigatran etexilate
,24666338,clearance,"Clearance of dabigatran via continuous veno-venous hemodiafiltration was calculated, using both the recovery and A-V pair methods, with a mean clearance of 58.1 and 31.9 ml/h, respectively, and a calculated mean extraction ratio of 0.2.",Use of continuous veno-venous haemodiafiltration therapy in dabigatran overdose. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24666338/),[ml] / [h],31.9,53239,DB06695,Dabigatran etexilate
,24666338,extraction ratio,"Clearance of dabigatran via continuous veno-venous hemodiafiltration was calculated, using both the recovery and A-V pair methods, with a mean clearance of 58.1 and 31.9 ml/h, respectively, and a calculated mean extraction ratio of 0.2.",Use of continuous veno-venous haemodiafiltration therapy in dabigatran overdose. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24666338/),,0.2,53240,DB06695,Dabigatran etexilate
,19696042,elimination half-life,"The elimination half-life is 12 to 14 hours, with clearance predominantly occurring via renal excretion of unchanged drug.","Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19696042/),h,12 to 14,56122,DB06695,Dabigatran etexilate
,26597179,peak effect,"The peak effect of edoxaban on prothrombin time (PT) after 4 days of edoxaban only was 21.8 ± 2.46 s; after switching from rivaroxaban to edoxaban, peak effect on PT was similar at 21.8 ± 2.88 s.",Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26597179/),s,21.8,56984,DB06695,Dabigatran etexilate
,26597179,peak effect,"The peak effect of edoxaban on prothrombin time (PT) after 4 days of edoxaban only was 21.8 ± 2.46 s; after switching from rivaroxaban to edoxaban, peak effect on PT was similar at 21.8 ± 2.88 s.",Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26597179/),s,21.8,56985,DB06695,Dabigatran etexilate
,26597179,least,"After switching from dabigatran etexilate to edoxaban, least squares mean activated partial thromboplastin time (aPTT) at 2 h after administration was 47.6 vs 35.0 s for edoxaban alone.",Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26597179/),s,47.6,56986,DB06695,Dabigatran etexilate
,26597179,activated partial thromboplastin time (aPTT),"After switching from dabigatran etexilate to edoxaban, least squares mean activated partial thromboplastin time (aPTT) at 2 h after administration was 47.6 vs 35.0 s for edoxaban alone.",Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26597179/),s,47.6,56987,DB06695,Dabigatran etexilate
,26597179,activated partial thromboplastin time (aPTT),"After switching from dabigatran etexilate to edoxaban, least squares mean activated partial thromboplastin time (aPTT) at 2 h after administration was 47.6 vs 35.0 s for edoxaban alone.",Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26597179/),s,35.0,56988,DB06695,Dabigatran etexilate
,20671233,terminal half-life,The terminal half-life of dabigatran is 12 to 14 hours in elderly volunteers.,Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20671233/),h,12 to 14,59588,DB06695,Dabigatran etexilate
exceeded,29055248,Extraction recoveries,Extraction recoveries exceeded 80 %.,Simultaneous quantification of direct oral anticoagulants currently used in anticoagulation therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29055248/),%,80,60787,DB06695,Dabigatran etexilate
,23210726,bioavailability,"The concomitant administration of clarithromycin induced a significant change only in DE bioavailability, which increased from 6.5% to 10.1% in the presence of clarithromycin.",A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23210726/),%,6.5,67035,DB06695,Dabigatran etexilate
,23210726,bioavailability,"The concomitant administration of clarithromycin induced a significant change only in DE bioavailability, which increased from 6.5% to 10.1% in the presence of clarithromycin.",A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23210726/),%,10.1,67036,DB06695,Dabigatran etexilate
,27396624,relative bioavailability,Optimized SNEDDS had 531.80% relative bioavailability compared with Pradaxa(®) capsules (a commercial DE product).,A solid self-nanoemulsifying system of the BCS class IIb drug dabigatran etexilate to improve oral bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27396624/),%,531.80,71588,DB06695,Dabigatran etexilate
,23389759,Cmax,Plasma concentration-time profiles were similar in both periods on Day 3 (Cmax: 176 and 159 ng/ml).,Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23389759/),[ng] / [ml],176,86684,DB06695,Dabigatran etexilate
,23389759,Cmax,Plasma concentration-time profiles were similar in both periods on Day 3 (Cmax: 176 and 159 ng/ml).,Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23389759/),[ng] / [ml],159,86685,DB06695,Dabigatran etexilate
,23389759,targeted blood flow,"Four hours of haemodialysis removed 48.8% and 59.3% of total dabigatran from the central compartment with 200 and 400 ml/minute targeted blood flow, respectively.",Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23389759/),[ml] / [min],200,86686,DB06695,Dabigatran etexilate
,23389759,targeted blood flow,"Four hours of haemodialysis removed 48.8% and 59.3% of total dabigatran from the central compartment with 200 and 400 ml/minute targeted blood flow, respectively.",Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23389759/),[ml] / [min],400,86687,DB06695,Dabigatran etexilate
,32474728,elimination half-life,"The plasma concentration of total dabigatran reached its maximum measured concentration at a median time of 3-4 h from the dose of interest (either the initial single dose on day 1 or the final dose on day 10) under fed conditions, and declined with an elimination half-life of 10.7-10.9 h following the dose of interest.",Pharmacokinetics and Safety of Dabigatran Etexilate after Single and Multiple Oral Doses in Healthy Chinese Subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32474728/),h,10.7-10.9,98646,DB06695,Dabigatran etexilate
,24846496,time (tmax ) to reach the,The median time (tmax ) to reach the maximum plasma-free dabigatran concentration (Cmax ) was 2 hours (range 1-3 hours).,An evaluation of oral dabigatran etexilate pharmacokinetics and pharmacodynamics in hemodialysis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24846496/),h,2,99542,DB06695,Dabigatran etexilate
,24846496,Cmax,The mean free dabigatran Cmax was 95.5 ± 33.4 ng/mL.,An evaluation of oral dabigatran etexilate pharmacokinetics and pharmacodynamics in hemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24846496/),[ng] / [ml],95.5,99543,DB06695,Dabigatran etexilate
,24846496,elimination half-lives,"The mean elimination half-lives on and off hemodialysis were, respectively, 2.6 ± 1.3 and 30.2 ± 7.8 hours.",An evaluation of oral dabigatran etexilate pharmacokinetics and pharmacodynamics in hemodialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24846496/),h,2.6,99544,DB06695,Dabigatran etexilate
,24846496,elimination half-lives,"The mean elimination half-lives on and off hemodialysis were, respectively, 2.6 ± 1.3 and 30.2 ± 7.8 hours.",An evaluation of oral dabigatran etexilate pharmacokinetics and pharmacodynamics in hemodialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24846496/),h,30.2,99545,DB06695,Dabigatran etexilate
,24846496,extraction ratio,Hemodialysis effectively removed dabigatran with an extraction ratio of 0.63 ± 0.07.,An evaluation of oral dabigatran etexilate pharmacokinetics and pharmacodynamics in hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24846496/),,0.63,99546,DB06695,Dabigatran etexilate
,24846496,maximal TT ratio,The maximal TT ratio was 2.1 and the TT ratio demonstrated a strong linear dependence on free dabigatran concentration (r(2) = 0.741).,An evaluation of oral dabigatran etexilate pharmacokinetics and pharmacodynamics in hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24846496/),,2.1,99547,DB06695,Dabigatran etexilate
≤,28488236,Plasma levels,Plasma levels ≤30 ng/ml were considered low.,"Dabigatran plasma levels, aPTT and thromboelastography in patients with AF: implications for allowing early non-elective surgical procedures. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28488236/),ng,30,102071,DB06695,Dabigatran etexilate
,28488236,aPTT,These patients compared to those with higher levels had significantly different aPTT (37.7 ± 4.4 vs. 49.6 ± 9.2 s; p < 0.001) and TEG R (6.7 ± 1.3 vs. 8.4 ± 2.6 min; p = 0.002).,"Dabigatran plasma levels, aPTT and thromboelastography in patients with AF: implications for allowing early non-elective surgical procedures. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28488236/),s,37.7,102072,DB06695,Dabigatran etexilate
,28488236,aPTT,These patients compared to those with higher levels had significantly different aPTT (37.7 ± 4.4 vs. 49.6 ± 9.2 s; p < 0.001) and TEG R (6.7 ± 1.3 vs. 8.4 ± 2.6 min; p = 0.002).,"Dabigatran plasma levels, aPTT and thromboelastography in patients with AF: implications for allowing early non-elective surgical procedures. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28488236/),s,49.6,102073,DB06695,Dabigatran etexilate
,28488236,aPTT,These patients compared to those with higher levels had significantly different aPTT (37.7 ± 4.4 vs. 49.6 ± 9.2 s; p < 0.001) and TEG R (6.7 ± 1.3 vs. 8.4 ± 2.6 min; p = 0.002).,"Dabigatran plasma levels, aPTT and thromboelastography in patients with AF: implications for allowing early non-elective surgical procedures. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28488236/),min,6.7,102074,DB06695,Dabigatran etexilate
,28488236,aPTT,These patients compared to those with higher levels had significantly different aPTT (37.7 ± 4.4 vs. 49.6 ± 9.2 s; p < 0.001) and TEG R (6.7 ± 1.3 vs. 8.4 ± 2.6 min; p = 0.002).,"Dabigatran plasma levels, aPTT and thromboelastography in patients with AF: implications for allowing early non-elective surgical procedures. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28488236/),min,8.4,102075,DB06695,Dabigatran etexilate
,28488236,R,These patients compared to those with higher levels had significantly different aPTT (37.7 ± 4.4 vs. 49.6 ± 9.2 s; p < 0.001) and TEG R (6.7 ± 1.3 vs. 8.4 ± 2.6 min; p = 0.002).,"Dabigatran plasma levels, aPTT and thromboelastography in patients with AF: implications for allowing early non-elective surgical procedures. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28488236/),min,6.7,102076,DB06695,Dabigatran etexilate
,28488236,R,These patients compared to those with higher levels had significantly different aPTT (37.7 ± 4.4 vs. 49.6 ± 9.2 s; p < 0.001) and TEG R (6.7 ± 1.3 vs. 8.4 ± 2.6 min; p = 0.002).,"Dabigatran plasma levels, aPTT and thromboelastography in patients with AF: implications for allowing early non-elective surgical procedures. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28488236/),min,8.4,102077,DB06695,Dabigatran etexilate
>,28488236,aPTT,Only three of the patients with low levels had an aPTT >40 s.,"Dabigatran plasma levels, aPTT and thromboelastography in patients with AF: implications for allowing early non-elective surgical procedures. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28488236/),s,40,102078,DB06695,Dabigatran etexilate
,17506785,half-lives,"This was followed by a rapid distribution/elimination phase and a terminal phase, with associated estimated half-lives of 8-10 h and 14-17 h with single and multiple dose administrations, respectively.","The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17506785/),h,8-10,103457,DB06695,Dabigatran etexilate
,17506785,half-lives,"This was followed by a rapid distribution/elimination phase and a terminal phase, with associated estimated half-lives of 8-10 h and 14-17 h with single and multiple dose administrations, respectively.","The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17506785/),h,14-17,103458,DB06695,Dabigatran etexilate
,17506785,apparent volume of distribution during the terminal phase (V(z)/F),"The mean apparent volume of distribution during the terminal phase (V(z)/F) of 1860 l (range 1430-2400 l) and the apparent total clearance after oral administration (CL(tot)/F) of 2031 ml min(-1) (range 1480-2430), were dose independent.","The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17506785/),l,1860,103459,DB06695,Dabigatran etexilate
,17506785,apparent total clearance after oral administration (CL(tot)/F),"The mean apparent volume of distribution during the terminal phase (V(z)/F) of 1860 l (range 1430-2400 l) and the apparent total clearance after oral administration (CL(tot)/F) of 2031 ml min(-1) (range 1480-2430), were dose independent.","The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17506785/),[ml] / [min],2031,103460,DB06695,Dabigatran etexilate
,26735702,half-life,"The half-life of dabigatran was not prolonged following overdose, being calculated between 7 and 11 h in each case.",Dabigatran deliberate overdose: two cases and suggestions for laboratory monitoring. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26735702/),h,7 and 11,105548,DB06695,Dabigatran etexilate
,25464103,flow rate,"The analysis was performed on an Ultimate TM XB-C18 (4.6×50mm, 5μm) column using gradient elution with a mobile phase composed of methanol containing 0.01% formic acid and pure water at a flow rate of 0.3mL/min.","Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of dabigatran etexilate, intermediate metabolite and dabigatran in 50μL rat plasma and its application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25464103/),[ml] / [min],0.3,109057,DB06695,Dabigatran etexilate
,27893182,AUC ratios,"ABCB1 genotype did not significantly affect drug pharmacokinetics: AUC ratios between mutant-allele carriers and wild-type volunteers were 1.27 (95% confidence interval [CI] 0.84-1.92) and 1.20 (95% CI 0.96-1.51) for dabigatran and rivaroxaban, respectively.",Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27893182/),,1.27,124437,DB06695,Dabigatran etexilate
,27893182,AUC ratios,"ABCB1 genotype did not significantly affect drug pharmacokinetics: AUC ratios between mutant-allele carriers and wild-type volunteers were 1.27 (95% confidence interval [CI] 0.84-1.92) and 1.20 (95% CI 0.96-1.51) for dabigatran and rivaroxaban, respectively.",Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27893182/),,1.20,124438,DB06695,Dabigatran etexilate
,29127863,Ctrough,"After 5days of dabigatran dosing, Ctrough and Cmax geometric means were 39μg/L (90% CI: 23-66) and 88μg/L (90% CI: 56-137), respectively; AUC0-12h was 958μg∗h/L (90% CI: 635-1445).",Pharmacokinetics of dabigatran etexilate and rivaroxaban in patients with short bowel syndrome requiring parenteral nutrition: The PDER PAN study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29127863/),[μg] / [l],39,126748,DB06695,Dabigatran etexilate
,29127863,Cmax,"After 5days of dabigatran dosing, Ctrough and Cmax geometric means were 39μg/L (90% CI: 23-66) and 88μg/L (90% CI: 56-137), respectively; AUC0-12h was 958μg∗h/L (90% CI: 635-1445).",Pharmacokinetics of dabigatran etexilate and rivaroxaban in patients with short bowel syndrome requiring parenteral nutrition: The PDER PAN study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29127863/),[μg] / [l],88,126749,DB06695,Dabigatran etexilate
,29127863,AUC0-12h,"After 5days of dabigatran dosing, Ctrough and Cmax geometric means were 39μg/L (90% CI: 23-66) and 88μg/L (90% CI: 56-137), respectively; AUC0-12h was 958μg∗h/L (90% CI: 635-1445).",Pharmacokinetics of dabigatran etexilate and rivaroxaban in patients with short bowel syndrome requiring parenteral nutrition: The PDER PAN study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29127863/),[μg∗h] / [l],958,126750,DB06695,Dabigatran etexilate
,29127863,Ctrough,"After 5days of rivaroxaban dosing, Ctrough and Cmax geometric means were 9μg/L (90% CI: 1-71) and 167μg/L (90% CI: 102-276), respectively; AUC0-24h was 1720μg∗h/L (90% CI: 899-3300).",Pharmacokinetics of dabigatran etexilate and rivaroxaban in patients with short bowel syndrome requiring parenteral nutrition: The PDER PAN study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29127863/),[μg] / [l],9,126751,DB06695,Dabigatran etexilate
,29127863,Cmax,"After 5days of rivaroxaban dosing, Ctrough and Cmax geometric means were 9μg/L (90% CI: 1-71) and 167μg/L (90% CI: 102-276), respectively; AUC0-24h was 1720μg∗h/L (90% CI: 899-3300).",Pharmacokinetics of dabigatran etexilate and rivaroxaban in patients with short bowel syndrome requiring parenteral nutrition: The PDER PAN study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29127863/),[μg] / [l],167,126752,DB06695,Dabigatran etexilate
,29127863,AUC0-24h,"After 5days of rivaroxaban dosing, Ctrough and Cmax geometric means were 9μg/L (90% CI: 1-71) and 167μg/L (90% CI: 102-276), respectively; AUC0-24h was 1720μg∗h/L (90% CI: 899-3300).",Pharmacokinetics of dabigatran etexilate and rivaroxaban in patients with short bowel syndrome requiring parenteral nutrition: The PDER PAN study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29127863/),[μg∗h] / [l],1720,126753,DB06695,Dabigatran etexilate
,29127863,Cmax ratio,"For dabigatran, Cmax ratio was 0.57 (SD 0.33) and Ctrough ratio was 0.35 (SD 0.44).",Pharmacokinetics of dabigatran etexilate and rivaroxaban in patients with short bowel syndrome requiring parenteral nutrition: The PDER PAN study. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29127863/),,0.57,126754,DB06695,Dabigatran etexilate
,29127863,Ctrough ratio,"For dabigatran, Cmax ratio was 0.57 (SD 0.33) and Ctrough ratio was 0.35 (SD 0.44).",Pharmacokinetics of dabigatran etexilate and rivaroxaban in patients with short bowel syndrome requiring parenteral nutrition: The PDER PAN study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29127863/),,0.35,126755,DB06695,Dabigatran etexilate
,23466964,IC2x LT,"Their inhibitory potencies, expressed as IC2x LT, IC2x TTP, IC50 ETP, IC50 peak thrombin, and IC50 Vmax, were as follows: 0.10 ± 0.01, 0.19 ± 0.02, 0.65 ± 0.11, 0.089 ± 0.019, and 0.049 ± 0.007 μM for apixaban; 0.049 ± 0.007, 0.070 ± 0.009, 0.43 ± 0.07, 0.048 ± 0.008, and 0.022 ± 0.005 μM for rivaroxaban; and 0.063 ± 0.019, 0.18 ± 0.06, 0.50 ± 0.08, 0.55 ± 0.06, and 0.57 ± 0.27 μM for dabigatran.",Inhibitory effect of apixaban compared with rivaroxaban and dabigatran on thrombin generation assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23466964/),μM,0.10,132118,DB06695,Dabigatran etexilate
,23466964,IC50 Vmax,"Their inhibitory potencies, expressed as IC2x LT, IC2x TTP, IC50 ETP, IC50 peak thrombin, and IC50 Vmax, were as follows: 0.10 ± 0.01, 0.19 ± 0.02, 0.65 ± 0.11, 0.089 ± 0.019, and 0.049 ± 0.007 μM for apixaban; 0.049 ± 0.007, 0.070 ± 0.009, 0.43 ± 0.07, 0.048 ± 0.008, and 0.022 ± 0.005 μM for rivaroxaban; and 0.063 ± 0.019, 0.18 ± 0.06, 0.50 ± 0.08, 0.55 ± 0.06, and 0.57 ± 0.27 μM for dabigatran.",Inhibitory effect of apixaban compared with rivaroxaban and dabigatran on thrombin generation assay. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23466964/),μM,0.063,132119,DB06695,Dabigatran etexilate
,23466964,IC50 Vmax,"Their inhibitory potencies, expressed as IC2x LT, IC2x TTP, IC50 ETP, IC50 peak thrombin, and IC50 Vmax, were as follows: 0.10 ± 0.01, 0.19 ± 0.02, 0.65 ± 0.11, 0.089 ± 0.019, and 0.049 ± 0.007 μM for apixaban; 0.049 ± 0.007, 0.070 ± 0.009, 0.43 ± 0.07, 0.048 ± 0.008, and 0.022 ± 0.005 μM for rivaroxaban; and 0.063 ± 0.019, 0.18 ± 0.06, 0.50 ± 0.08, 0.55 ± 0.06, and 0.57 ± 0.27 μM for dabigatran.",Inhibitory effect of apixaban compared with rivaroxaban and dabigatran on thrombin generation assay. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23466964/),μM,0.18,132120,DB06695,Dabigatran etexilate
,23466964,IC50 Vmax,"Their inhibitory potencies, expressed as IC2x LT, IC2x TTP, IC50 ETP, IC50 peak thrombin, and IC50 Vmax, were as follows: 0.10 ± 0.01, 0.19 ± 0.02, 0.65 ± 0.11, 0.089 ± 0.019, and 0.049 ± 0.007 μM for apixaban; 0.049 ± 0.007, 0.070 ± 0.009, 0.43 ± 0.07, 0.048 ± 0.008, and 0.022 ± 0.005 μM for rivaroxaban; and 0.063 ± 0.019, 0.18 ± 0.06, 0.50 ± 0.08, 0.55 ± 0.06, and 0.57 ± 0.27 μM for dabigatran.",Inhibitory effect of apixaban compared with rivaroxaban and dabigatran on thrombin generation assay. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23466964/),μM,0.50,132121,DB06695,Dabigatran etexilate
,23466964,IC50 Vmax,"Their inhibitory potencies, expressed as IC2x LT, IC2x TTP, IC50 ETP, IC50 peak thrombin, and IC50 Vmax, were as follows: 0.10 ± 0.01, 0.19 ± 0.02, 0.65 ± 0.11, 0.089 ± 0.019, and 0.049 ± 0.007 μM for apixaban; 0.049 ± 0.007, 0.070 ± 0.009, 0.43 ± 0.07, 0.048 ± 0.008, and 0.022 ± 0.005 μM for rivaroxaban; and 0.063 ± 0.019, 0.18 ± 0.06, 0.50 ± 0.08, 0.55 ± 0.06, and 0.57 ± 0.27 μM for dabigatran.",Inhibitory effect of apixaban compared with rivaroxaban and dabigatran on thrombin generation assay. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23466964/),μM,0.55,132122,DB06695,Dabigatran etexilate
,15831779,AUC(0-infinity),A decrease in the mean dabigatran AUC(0-infinity) (904 to 705 ng*h/mL) occurred with coadministration of pantoprazole.,Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831779/),[h·ng] / [ml],904 to 705,140325,DB06695,Dabigatran etexilate
,19875005,bioavailability,"The main pharmacokinetic characteristics of dabigatran are a bioavailability of approximately 7.5%, a maximum concentration obtained in 0.5 to 2 hours, a terminal half-life of elimination of 7 to 17 hours, a renal way of elimination, 80% as unchanged form and 20% as glucuronide conjugate.",[Dabigatran: clinical pharmacology]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19875005/),%,7.5,140899,DB06695,Dabigatran etexilate
,19875005,terminal half-life of elimination,"The main pharmacokinetic characteristics of dabigatran are a bioavailability of approximately 7.5%, a maximum concentration obtained in 0.5 to 2 hours, a terminal half-life of elimination of 7 to 17 hours, a renal way of elimination, 80% as unchanged form and 20% as glucuronide conjugate.",[Dabigatran: clinical pharmacology]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19875005/),h,7 to 17,140900,DB06695,Dabigatran etexilate
,17322149,CL/F,"The typical values for CL/F for a patient with gastrin of 34.58 pmol/L and creatinine clearance of 76.16 mL/min were 70.87 and 106.2 L/h on days 0 and 1 and days 2 to 10, respectively.",Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17322149/),[pM] / [l],34.58,144018,DB06695,Dabigatran etexilate
,17322149,CL/F,"The typical values for CL/F for a patient with gastrin of 34.58 pmol/L and creatinine clearance of 76.16 mL/min were 70.87 and 106.2 L/h on days 0 and 1 and days 2 to 10, respectively.",Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17322149/),[l] / [h],70.87,144019,DB06695,Dabigatran etexilate
,17322149,CL/F,"The typical values for CL/F for a patient with gastrin of 34.58 pmol/L and creatinine clearance of 76.16 mL/min were 70.87 and 106.2 L/h on days 0 and 1 and days 2 to 10, respectively.",Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17322149/),[l] / [h],106.2,144020,DB06695,Dabigatran etexilate
,22177763,half-life,"The half-life is around 8 to 12 hours, with a peak activity 2 to 4 hours after ingestion.",[Pharmacologic heterogeneity of new anticoagulants]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22177763/),h,8 to 12,148054,DB06695,Dabigatran etexilate
,25815177,blood concentrations,He underwent HDF and dabigatran blood concentrations decreased from 325.3 ng/mL to 160.5 ng/mL.,Venovenous haemodiafiltration for the management of dabigatran overdose in intensive care unit. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25815177/),[ng] / [ml],325.3,148999,DB06695,Dabigatran etexilate
,25815177,blood concentrations,He underwent HDF and dabigatran blood concentrations decreased from 325.3 ng/mL to 160.5 ng/mL.,Venovenous haemodiafiltration for the management of dabigatran overdose in intensive care unit. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25815177/),[ng] / [ml],160.5,149000,DB06695,Dabigatran etexilate
,21481181,IC(50),"S35972 inhibited human thrombin with an IC(50) of 3.7 nm, and did not inhibit other serine proteases.","S35972, a direct-acting thrombin inhibitor with high oral bioavailability and antithrombotic efficacy. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21481181/),nm,3.7,163436,DB06695,Dabigatran etexilate
,21481181,bioavailability,"In the fasted dog, oral administration of 3 mg kg(-1) S35972 increased TT rapidly and for at least 8 h, and its pharmacologic bioavailability was 75.4% ± 0.1%.","S35972, a direct-acting thrombin inhibitor with high oral bioavailability and antithrombotic efficacy. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21481181/),%,75.4,163437,DB06695,Dabigatran etexilate
,24807346,fetal-to-maternal,"There was slower transfer of dabigatran compared with antipyrine from the maternal-to-fetal circulation, because the median fetal-to-maternal concentration ratio was 0.33 (interquartile range 0.29-0.38) after 3 hours (n=3).",Transfer of dabigatran and dabigatran etexilate mesylate across the dually perfused human placenta. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24807346/),,0.33,164557,DB06695,Dabigatran etexilate
,24807346,concentration ratio,"There was slower transfer of dabigatran compared with antipyrine from the maternal-to-fetal circulation, because the median fetal-to-maternal concentration ratio was 0.33 (interquartile range 0.29-0.38) after 3 hours (n=3).",Transfer of dabigatran and dabigatran etexilate mesylate across the dually perfused human placenta. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24807346/),,0.33,164558,DB06695,Dabigatran etexilate
,24807346,f,"The prodrug, dabigatran etexilate mesylate, had limited placental transfer as characterized by a fetal-to-maternal ratio of 0.17 (interquartile range 0.15-0.17) after 3 hours (n=3).",Transfer of dabigatran and dabigatran etexilate mesylate across the dually perfused human placenta. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24807346/),,0.17,164559,DB06695,Dabigatran etexilate
,17598008,Ki,"These studies demonstrated that dabigatran selectively and reversibly inhibited human thrombin (Ki: 4.5 nM) as well as thrombin-induced platelet aggregation (IC(50): 10 nM), while showing no inhibitory effect on other platelet-stimulating agents.","In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17598008/),nM,4.5,166896,DB06695,Dabigatran etexilate
,17598008,IC(50),"These studies demonstrated that dabigatran selectively and reversibly inhibited human thrombin (Ki: 4.5 nM) as well as thrombin-induced platelet aggregation (IC(50): 10 nM), while showing no inhibitory effect on other platelet-stimulating agents.","In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17598008/),nM,10,166897,DB06695,Dabigatran etexilate
,17598008,IC(50),"Thrombin generation in platelet-poor plasma (PPP), measured as the endogenous thrombin potential (ETP) was inhibited concentration-dependently (IC(50): 0.56 microM).","In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17598008/),μM,0.56,166898,DB06695,Dabigatran etexilate
,17598008,maximum effects,"Dose- and time-dependent anticoagulant effects were observed with dabigatran etexilate administered orally to conscious rats (10, 20 and 50 mg/kg) or rhesus monkeys (1, 2.5 or 5 mg/kg), with maximum effects observed between 30 and 120 min after administration, respectively.","In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17598008/),min,30,166899,DB06695,Dabigatran etexilate
,17598008,maximum effects,"Dose- and time-dependent anticoagulant effects were observed with dabigatran etexilate administered orally to conscious rats (10, 20 and 50 mg/kg) or rhesus monkeys (1, 2.5 or 5 mg/kg), with maximum effects observed between 30 and 120 min after administration, respectively.","In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17598008/),min,120,166900,DB06695,Dabigatran etexilate
,22782539,bioavailability,"Similarly, clopidogrel bioavailability remained unchanged by chronic administration of dabigatran etexilate (part 3: ratio test/reference for AUC(0-24) was 103%; 90% CI 80.3-131%), as did its pharmacodynamic effects on the inhibition of platelet aggregation.",Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22782539/),%,103,180838,DB06695,Dabigatran etexilate
,32691242,area under the plasma concentration-time curve (AUC0-∞),"The geometric mean (gMean) values of area under the plasma concentration-time curve (AUC0-∞) and maximum concentration (Cmax) were 44,200 nmol h/L and 30,900 nmol/L, respectively.","Idarucizumab Reverses Dabigatran Anticoagulant Activity in Healthy Chinese Volunteers: A Pharmacokinetics, Pharmacodynamics, and Safety Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32691242/),[h·nM] / [l],"44,200",188645,DB06695,Dabigatran etexilate
,32691242,maximum concentration (Cmax),"The geometric mean (gMean) values of area under the plasma concentration-time curve (AUC0-∞) and maximum concentration (Cmax) were 44,200 nmol h/L and 30,900 nmol/L, respectively.","Idarucizumab Reverses Dabigatran Anticoagulant Activity in Healthy Chinese Volunteers: A Pharmacokinetics, Pharmacodynamics, and Safety Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32691242/),[nM] / [l],"30,900",188646,DB06695,Dabigatran etexilate
,32691242,"area under the effect (AUECabove,2-12","The area under the effect (AUECabove,2-12) in the presence and absence of idarucizumab was close to zero for all coagulation parameters, diluted thrombin time (dTT), ecarin clotting time (ECT), activated partial thromboplastin time (aPTT), and thrombin time (TT), which indicated the reversal of dabigatran anticoagulation by idarucizumab.","Idarucizumab Reverses Dabigatran Anticoagulant Activity in Healthy Chinese Volunteers: A Pharmacokinetics, Pharmacodynamics, and Safety Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32691242/),,zero,188647,DB06695,Dabigatran etexilate
,29695165,excretion,"Dabigatran excretion is 80% renal, so exposure increases with severity of renal failure.",Pharmacokinetics/Pharmacodynamics of Dabigatran 75 mg Twice Daily in Patients With Nonvalvular Atrial Fibrillation and Severely Impaired Renal Function. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29695165/),,80,194876,DB06695,Dabigatran etexilate
,29695165,"Cpre,ss","Cpre,ss values (n = 51) were close to pharmacokinetic modeling predictions with a geometric mean (gMean) of 155 ng/mL, geometric coefficient of variation (gCV) of 76.9%, and range of 15.6 to 498 ng/mL.",Pharmacokinetics/Pharmacodynamics of Dabigatran 75 mg Twice Daily in Patients With Nonvalvular Atrial Fibrillation and Severely Impaired Renal Function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29695165/),[ng] / [ml],155,194877,DB06695,Dabigatran etexilate
,29695165,"C2,ss","The C2,ss values (n = 59) had a gMean of 202 ng/mL, gCV of 70.6%, and range of 42.0 to 680 ng/mL.",Pharmacokinetics/Pharmacodynamics of Dabigatran 75 mg Twice Daily in Patients With Nonvalvular Atrial Fibrillation and Severely Impaired Renal Function. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29695165/),[ng] / [ml],202,194878,DB06695,Dabigatran etexilate
,29695165,"Cpre, ss","Eleven (18.3%) patients had ≥1 adverse event (AE); pharmacokinetic results for these patients versus those without AEs (n = 49) were Cpre, ss: gMean = 206 versus 145 ng/mL, gCV = 64.0% versus 78.3%; C2,ss: gMean = 243 versus 193 ng/mL, gCV = 68.9% versus 70.8%.",Pharmacokinetics/Pharmacodynamics of Dabigatran 75 mg Twice Daily in Patients With Nonvalvular Atrial Fibrillation and Severely Impaired Renal Function. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29695165/),[ng] / [ml],206,194879,DB06695,Dabigatran etexilate
,29695165,"Cpre, ss","Eleven (18.3%) patients had ≥1 adverse event (AE); pharmacokinetic results for these patients versus those without AEs (n = 49) were Cpre, ss: gMean = 206 versus 145 ng/mL, gCV = 64.0% versus 78.3%; C2,ss: gMean = 243 versus 193 ng/mL, gCV = 68.9% versus 70.8%.",Pharmacokinetics/Pharmacodynamics of Dabigatran 75 mg Twice Daily in Patients With Nonvalvular Atrial Fibrillation and Severely Impaired Renal Function. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29695165/),[ng] / [ml],145,194880,DB06695,Dabigatran etexilate
,29695165,"C2,ss","Eleven (18.3%) patients had ≥1 adverse event (AE); pharmacokinetic results for these patients versus those without AEs (n = 49) were Cpre, ss: gMean = 206 versus 145 ng/mL, gCV = 64.0% versus 78.3%; C2,ss: gMean = 243 versus 193 ng/mL, gCV = 68.9% versus 70.8%.",Pharmacokinetics/Pharmacodynamics of Dabigatran 75 mg Twice Daily in Patients With Nonvalvular Atrial Fibrillation and Severely Impaired Renal Function. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29695165/),[ng] / [ml],243,194881,DB06695,Dabigatran etexilate
,29695165,"C2,ss","Eleven (18.3%) patients had ≥1 adverse event (AE); pharmacokinetic results for these patients versus those without AEs (n = 49) were Cpre, ss: gMean = 206 versus 145 ng/mL, gCV = 64.0% versus 78.3%; C2,ss: gMean = 243 versus 193 ng/mL, gCV = 68.9% versus 70.8%.",Pharmacokinetics/Pharmacodynamics of Dabigatran 75 mg Twice Daily in Patients With Nonvalvular Atrial Fibrillation and Severely Impaired Renal Function. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29695165/),[ng] / [ml],193,194882,DB06695,Dabigatran etexilate
,29202215,plasma concentrations,The geometric mean (gMean) total dabigatran plasma concentrations 2 hours post-dose (around peak concentrations) were 120 ng/mL with a geometric coefficient of variation (gCV) of 62.1%.,"Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate Oral Liquid Formulation in Infants with Venous Thromboembolism. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29202215/),[ng] / [ml],120,196934,DB06695,Dabigatran etexilate
,30349887,peak concentrations,"The median peak concentrations (IQR) were 148 ng/mL (138-240), 138 ng/mL (123-156.5), 215 ng/mL (181-249) for apixaban, dabigatran, and rivaroxaban, respectively.",Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: A retrospective study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30349887/),[ng] / [ml],148,199974,DB06695,Dabigatran etexilate
,30349887,peak concentrations,"The median peak concentrations (IQR) were 148 ng/mL (138-240), 138 ng/mL (123-156.5), 215 ng/mL (181-249) for apixaban, dabigatran, and rivaroxaban, respectively.",Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: A retrospective study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30349887/),[ng] / [ml],138,199975,DB06695,Dabigatran etexilate
,30349887,peak concentrations,"The median peak concentrations (IQR) were 148 ng/mL (138-240), 138 ng/mL (123-156.5), 215 ng/mL (181-249) for apixaban, dabigatran, and rivaroxaban, respectively.",Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: A retrospective study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30349887/),[ng] / [ml],215,199976,DB06695,Dabigatran etexilate
,31667735,AUC0-tz,"In the relative BA study, the gMeans of AUC0-tz (667 to 192 ng h/mL) and Cmax (83.1 to 21.8 ng/mL) were decreased by approximately 70% when the tablet was administered under rabeprazole pretreatment.",Bioequivalence of a Newly Developed Dabigatran Etexilate Tablet Versus the Commercial Capsule and Impact of Rabeprazole-Induced Elevated Gastric pH on Exposure in Healthy Subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31667735/),[h·ng] / [ml],667 to 192,205989,DB06695,Dabigatran etexilate
,31667735,Cmax,"In the relative BA study, the gMeans of AUC0-tz (667 to 192 ng h/mL) and Cmax (83.1 to 21.8 ng/mL) were decreased by approximately 70% when the tablet was administered under rabeprazole pretreatment.",Bioequivalence of a Newly Developed Dabigatran Etexilate Tablet Versus the Commercial Capsule and Impact of Rabeprazole-Induced Elevated Gastric pH on Exposure in Healthy Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31667735/),[ng] / [ml],83.1 to 21.8,205990,DB06695,Dabigatran etexilate
,32053549,absolute recoveries,"For all 3 anticoagulants and corresponding isotopically labeled internal standards, the absolute recoveries were similar and consistent, with mean values of 93%-102%.","Simultaneous Determination of Dabigatran, Rivaroxaban, and Apixaban in Human Plasma by Liquid Chromatography/Tandem Mass Spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32053549/),%,93,209618,DB06695,Dabigatran etexilate
,32053549,absolute recoveries,"For all 3 anticoagulants and corresponding isotopically labeled internal standards, the absolute recoveries were similar and consistent, with mean values of 93%-102%.","Simultaneous Determination of Dabigatran, Rivaroxaban, and Apixaban in Human Plasma by Liquid Chromatography/Tandem Mass Spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32053549/),%,102,209619,DB06695,Dabigatran etexilate
,31328179,AUC ss,"For these patients there was a decreased risk of hemorrhage (0.51, 0.32-0.79) when dabigatran AUC ss was in the second quartile range of 1.70 to 1.96 mg h/L and thromboembolism/CVA (0.34, 0.16-0.76) when in the third quartile range of 1.97 to 2.26 mg h/L.",Exposure Response Supports Therapeutic Drug Monitoring for Dabigatran Etexilate in Patients with Atrial Fibrillation. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31328179/),[h·mg] / [l],1.70 to 1.96,209911,DB06695,Dabigatran etexilate
,31328179,AUC ss,"An increased risk of hemorrhage (1.68, 1.18-2.38) was observed when AUC ss was in the fourth quartile range of 2.27 to 12.76 mg h/L.",Exposure Response Supports Therapeutic Drug Monitoring for Dabigatran Etexilate in Patients with Atrial Fibrillation. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31328179/),[h·mg] / [l],2.27 to 12.76,209912,DB06695,Dabigatran etexilate
,31328179,AUC ss,"An exposure-response relationship for dabigatran etexilate was described, where the most effective response was observed when AUC ss was in the range of 1.70 to 2.26 mg h/L.",Exposure Response Supports Therapeutic Drug Monitoring for Dabigatran Etexilate in Patients with Atrial Fibrillation. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31328179/),[h·mg] / [l],1.70 to 2.26,209913,DB06695,Dabigatran etexilate
,24861792,time to peak level,"The direct thrombin inhibitor, dabigatran, as well as the direct factor Xa inhibtors rivaroxaban, apixaban, and edoxaban, display pharmacodynamic features quite similar to low-molecular-weight heparins, with a time to peak level of 1-4 hours after oral administration, and a half-life between 5 and 14 hours.","Direct oral anticoagulants--pharmacology, drug interactions, and side effects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24861792/),h,1-4,211970,DB06695,Dabigatran etexilate
,24861792,half-life,"The direct thrombin inhibitor, dabigatran, as well as the direct factor Xa inhibtors rivaroxaban, apixaban, and edoxaban, display pharmacodynamic features quite similar to low-molecular-weight heparins, with a time to peak level of 1-4 hours after oral administration, and a half-life between 5 and 14 hours.","Direct oral anticoagulants--pharmacology, drug interactions, and side effects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24861792/),h,5 and 14,211971,DB06695,Dabigatran etexilate
,24861792,re,"Major differences are the extent of renal elimination (with 80% or more for dabigatran, 66% for rivaroxaban [33% unchanged, active drug, and 33% inactive metabolites], 33% for edoxaban, and finally, 25% for apixaban), and bioavailability, which determines the amount of drug required for attaining the target plasma concentration of the drug.","Direct oral anticoagulants--pharmacology, drug interactions, and side effects. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24861792/),%,66,211972,DB06695,Dabigatran etexilate
,24861792,re,"Major differences are the extent of renal elimination (with 80% or more for dabigatran, 66% for rivaroxaban [33% unchanged, active drug, and 33% inactive metabolites], 33% for edoxaban, and finally, 25% for apixaban), and bioavailability, which determines the amount of drug required for attaining the target plasma concentration of the drug.","Direct oral anticoagulants--pharmacology, drug interactions, and side effects. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24861792/),%,33,211973,DB06695,Dabigatran etexilate
,24861792,re,"Major differences are the extent of renal elimination (with 80% or more for dabigatran, 66% for rivaroxaban [33% unchanged, active drug, and 33% inactive metabolites], 33% for edoxaban, and finally, 25% for apixaban), and bioavailability, which determines the amount of drug required for attaining the target plasma concentration of the drug.","Direct oral anticoagulants--pharmacology, drug interactions, and side effects. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24861792/),%,25,211974,DB06695,Dabigatran etexilate
,29736814,trough levels,There were significant differences in dabigatran trough levels when comparing elderly patients on reduced dabigatran with non-elderly patients on reduced dabigatran (99.3 ± 73.6 vs 51.6 ± 25.6 ng/mL; p < 0.01).,Dabigatran Levels in Elderly Patients with Atrial Fibrillation: First Post-Marketing Experiences. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29736814/),[ng] / [ml],99.3,225386,DB06695,Dabigatran etexilate
,29736814,trough levels,There were significant differences in dabigatran trough levels when comparing elderly patients on reduced dabigatran with non-elderly patients on reduced dabigatran (99.3 ± 73.6 vs 51.6 ± 25.6 ng/mL; p < 0.01).,Dabigatran Levels in Elderly Patients with Atrial Fibrillation: First Post-Marketing Experiences. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29736814/),[ng] / [ml],51.6,225387,DB06695,Dabigatran etexilate
,29736814,peak levels,"Similarly, the detected dabigatran peak levels were significantly higher in elderly patients on reduced dabigatran compared with non-elderly patients on reduced dabigatran (173.4 ± 116.2 vs 116.1 ± 19.1 ng/mL; p < 0.01).",Dabigatran Levels in Elderly Patients with Atrial Fibrillation: First Post-Marketing Experiences. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29736814/),[ng] / [ml],173.4,225388,DB06695,Dabigatran etexilate
,29736814,peak levels,"Similarly, the detected dabigatran peak levels were significantly higher in elderly patients on reduced dabigatran compared with non-elderly patients on reduced dabigatran (173.4 ± 116.2 vs 116.1 ± 19.1 ng/mL; p < 0.01).",Dabigatran Levels in Elderly Patients with Atrial Fibrillation: First Post-Marketing Experiences. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29736814/),[ng] / [ml],116.1,225389,DB06695,Dabigatran etexilate
,28452843,trough level,"There were significant differences in dabigatran trough level comparing patients treated with PPI and patients without PPI (58.86 ± 36.76 ng/mL vs. 110.72 ± 88.47 ng/mL, P < 0.05).",The Impact of Proton Pump Inhibition on Dabigatran Levels in Patients With Atrial Fibrillation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28452843/),[ng] / [ml],58.86,229739,DB06695,Dabigatran etexilate
,28452843,trough level,"There were significant differences in dabigatran trough level comparing patients treated with PPI and patients without PPI (58.86 ± 36.76 ng/mL vs. 110.72 ± 88.47 ng/mL, P < 0.05).",The Impact of Proton Pump Inhibition on Dabigatran Levels in Patients With Atrial Fibrillation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28452843/),[ng] / [ml],110.72,229740,DB06695,Dabigatran etexilate
,28452843,peak level,"Similarly, there were significant differences in dabigatran peak level between compared groups (88.0 ± 20.5 ng/mL vs. 174.4 ± 139.64 ng/mL, P < 0.05).",The Impact of Proton Pump Inhibition on Dabigatran Levels in Patients With Atrial Fibrillation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28452843/),[ng] / [ml],88.0,229741,DB06695,Dabigatran etexilate
,28452843,peak level,"Similarly, there were significant differences in dabigatran peak level between compared groups (88.0 ± 20.5 ng/mL vs. 174.4 ± 139.64 ng/mL, P < 0.05).",The Impact of Proton Pump Inhibition on Dabigatran Levels in Patients With Atrial Fibrillation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28452843/),[ng] / [ml],174.4,229742,DB06695,Dabigatran etexilate
,22186806,total exposure (i.,"In pooled data from 14 phase I trials, total exposure (i.e. area under the plasma concentration-time curve [AUC]) after administration of dabigatran 150 mg once or twice-daily was on average 20% higher in Japanese than Caucasian subjects (median [10th to 90th percentile] 1,110 [644-1,824] vs. 924 [420-1,654] ng·h/ml) although the difference between the groups was not significant.",Pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects after oral administration of dabigatran etexilate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22186806/),[h·ng] / [ml],"1,110",230282,DB06695,Dabigatran etexilate
,22186806,total exposure (i.,"In pooled data from 14 phase I trials, total exposure (i.e. area under the plasma concentration-time curve [AUC]) after administration of dabigatran 150 mg once or twice-daily was on average 20% higher in Japanese than Caucasian subjects (median [10th to 90th percentile] 1,110 [644-1,824] vs. 924 [420-1,654] ng·h/ml) although the difference between the groups was not significant.",Pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects after oral administration of dabigatran etexilate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22186806/),[h·ng] / [ml],924,230283,DB06695,Dabigatran etexilate
,22186806,area under the plasma concentration-time curve [AUC],"In pooled data from 14 phase I trials, total exposure (i.e. area under the plasma concentration-time curve [AUC]) after administration of dabigatran 150 mg once or twice-daily was on average 20% higher in Japanese than Caucasian subjects (median [10th to 90th percentile] 1,110 [644-1,824] vs. 924 [420-1,654] ng·h/ml) although the difference between the groups was not significant.",Pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects after oral administration of dabigatran etexilate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22186806/),[h·ng] / [ml],"1,110",230284,DB06695,Dabigatran etexilate
,22186806,area under the plasma concentration-time curve [AUC],"In pooled data from 14 phase I trials, total exposure (i.e. area under the plasma concentration-time curve [AUC]) after administration of dabigatran 150 mg once or twice-daily was on average 20% higher in Japanese than Caucasian subjects (median [10th to 90th percentile] 1,110 [644-1,824] vs. 924 [420-1,654] ng·h/ml) although the difference between the groups was not significant.",Pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects after oral administration of dabigatran etexilate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22186806/),[h·ng] / [ml],924,230285,DB06695,Dabigatran etexilate
,22186806,trough concentrations,"In patients with AF, trough concentrations after administration of 150 mg twice-daily were similar in Japanese and Caucasian subjects (80.1 [34.5-193.8] vs. 71.0 [34.0-190] ng/ml).",Pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects after oral administration of dabigatran etexilate. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22186806/),[ng] / [ml],80.1,230286,DB06695,Dabigatran etexilate
,22186806,trough concentrations,"In patients with AF, trough concentrations after administration of 150 mg twice-daily were similar in Japanese and Caucasian subjects (80.1 [34.5-193.8] vs. 71.0 [34.0-190] ng/ml).",Pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects after oral administration of dabigatran etexilate. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22186806/),[ng] / [ml],71.0,230287,DB06695,Dabigatran etexilate
,12974871,Oral bioavailability,"Oral bioavailability, measured as the plasma concentration of the active metabolite, seems to be higher for ximelagatran (20%) than for BIBR 1048 (estimated to 5%).",Oral direct thrombin inhibitors in clinical development. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12974871/),%,20,230458,DB06695,Dabigatran etexilate
,12974871,Oral bioavailability,"Oral bioavailability, measured as the plasma concentration of the active metabolite, seems to be higher for ximelagatran (20%) than for BIBR 1048 (estimated to 5%).",Oral direct thrombin inhibitors in clinical development. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12974871/),%,5,230459,DB06695,Dabigatran etexilate
,12974871,half-life,"BIBR 953 has a longer half-life (about 12 h) than does melagatran (3-5 h) after oral administration of BIBR 1048 and ximelagatran, respectively.",Oral direct thrombin inhibitors in clinical development. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12974871/),h,12,230460,DB06695,Dabigatran etexilate
,12974871,half-life,"BIBR 953 has a longer half-life (about 12 h) than does melagatran (3-5 h) after oral administration of BIBR 1048 and ximelagatran, respectively.",Oral direct thrombin inhibitors in clinical development. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12974871/),h,3-5,230461,DB06695,Dabigatran etexilate
,17061960,aPTT,Mean baseline aPTT was 33.4 s and E(max) (maximum increase in aPTT contributed by the E(max) model) was 26.9 s.,Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17061960/),,33.4,255775,DB06695,Dabigatran etexilate
,17061960,E(max),Mean baseline aPTT was 33.4 s and E(max) (maximum increase in aPTT contributed by the E(max) model) was 26.9 s.,Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17061960/),s,26.9,255776,DB06695,Dabigatran etexilate
,17061960,concentration needed to attain 50% of maximum effect (EC(50)),The dabigatran concentration needed to attain 50% of maximum effect (EC(50)) was 94.7 ng ml(-1) and the mean slope of the linear concentration-response relationship (SLOP) was 0.0509 s ng(-1) ml(-1).,Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17061960/),[ng] / [ml],94.7,255777,DB06695,Dabigatran etexilate
,17061960,slope of the linear concentration-response relationship,The dabigatran concentration needed to attain 50% of maximum effect (EC(50)) was 94.7 ng ml(-1) and the mean slope of the linear concentration-response relationship (SLOP) was 0.0509 s ng(-1) ml(-1).,Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17061960/),[s] / [ml·ng],0.0509,255778,DB06695,Dabigatran etexilate
,17061960,SLOP,"SLOP decreased from 0.38 to 0.27 s ng(-1) ml(-1) with a half-life of 1.1 day, indicating greater PD effects on the day of surgery.",Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17061960/),[s] / [ml·ng],0.38,255779,DB06695,Dabigatran etexilate
,17061960,SLOP,"SLOP decreased from 0.38 to 0.27 s ng(-1) ml(-1) with a half-life of 1.1 day, indicating greater PD effects on the day of surgery.",Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17061960/),[s] / [ml·ng],0.27,255780,DB06695,Dabigatran etexilate
,17061960,half-life,"SLOP decreased from 0.38 to 0.27 s ng(-1) ml(-1) with a half-life of 1.1 day, indicating greater PD effects on the day of surgery.",Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17061960/),d,1.1,255781,DB06695,Dabigatran etexilate
,25789661,half-life,"Maximum plasma concentrations were achieved near the end of infusion, followed by a rapid decline, with an initial idarucizumab half-life of ~45 minutes.","A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25789661/),min,45,258253,DB06695,Dabigatran etexilate
,27717999,AUCinf,"Dabigatran EM monotherapy and concurrent administration of dabigatran EM with bosutinib resulted in similar values for concentration time curves from time zero extrapolated to infinity (AUCinf), but slightly lower maximum plasma concentration (C max) values (AUCinf, 1182 and 1186 ng·h/mL, respectively; C max, 129.8 and 114.1 ng/mL).","Effect of bosutinib on the absorption of dabigatran etexilate mesylate, a P-glycoprotein substrate, in healthy subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27717999/),[h·ng] / [ml],1182,260008,DB06695,Dabigatran etexilate
,27717999,AUCinf,"Dabigatran EM monotherapy and concurrent administration of dabigatran EM with bosutinib resulted in similar values for concentration time curves from time zero extrapolated to infinity (AUCinf), but slightly lower maximum plasma concentration (C max) values (AUCinf, 1182 and 1186 ng·h/mL, respectively; C max, 129.8 and 114.1 ng/mL).","Effect of bosutinib on the absorption of dabigatran etexilate mesylate, a P-glycoprotein substrate, in healthy subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27717999/),[h·ng] / [ml],1186,260009,DB06695,Dabigatran etexilate
,27717999,C max,"Dabigatran EM monotherapy and concurrent administration of dabigatran EM with bosutinib resulted in similar values for concentration time curves from time zero extrapolated to infinity (AUCinf), but slightly lower maximum plasma concentration (C max) values (AUCinf, 1182 and 1186 ng·h/mL, respectively; C max, 129.8 and 114.1 ng/mL).","Effect of bosutinib on the absorption of dabigatran etexilate mesylate, a P-glycoprotein substrate, in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27717999/),[ng] / [ml],129.8,260010,DB06695,Dabigatran etexilate
,27717999,C max,"Dabigatran EM monotherapy and concurrent administration of dabigatran EM with bosutinib resulted in similar values for concentration time curves from time zero extrapolated to infinity (AUCinf), but slightly lower maximum plasma concentration (C max) values (AUCinf, 1182 and 1186 ng·h/mL, respectively; C max, 129.8 and 114.1 ng/mL).","Effect of bosutinib on the absorption of dabigatran etexilate mesylate, a P-glycoprotein substrate, in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27717999/),[ng] / [ml],114.1,260011,DB06695,Dabigatran etexilate
,27717999,time to maximum concentration,The time to maximum concentration for dabigatran was 2.99 and 3.99 h for combination therapy.,"Effect of bosutinib on the absorption of dabigatran etexilate mesylate, a P-glycoprotein substrate, in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27717999/),h,2.99,260012,DB06695,Dabigatran etexilate
,27717999,time to maximum concentration,The time to maximum concentration for dabigatran was 2.99 and 3.99 h for combination therapy.,"Effect of bosutinib on the absorption of dabigatran etexilate mesylate, a P-glycoprotein substrate, in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27717999/),h,3.99,260013,DB06695,Dabigatran etexilate
,27559839,Ctrough,"Among the 38 patients studied, Ctrough of dabigatran and CLcr were scattered in a range from 31.4 to 329.5 ng/mL and 15.4-133.4 mL/min, respectively.",Dosage Adjustment of Dabigatran Etexilate Based on Creatinine Clearance in Patients With Cardioembolic Stroke or Atrial Fibrillation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27559839/),[ng] / [ml],31.4 to 329.5,260194,DB06695,Dabigatran etexilate
,27559839,CLcr,"Among the 38 patients studied, Ctrough of dabigatran and CLcr were scattered in a range from 31.4 to 329.5 ng/mL and 15.4-133.4 mL/min, respectively.",Dosage Adjustment of Dabigatran Etexilate Based on Creatinine Clearance in Patients With Cardioembolic Stroke or Atrial Fibrillation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27559839/),[ml] / [min],15.4-133.4,260195,DB06695,Dabigatran etexilate
,27559839,Ctrough,"Based on the findings, the daily dose of dabigatran etexilate that provides Ctrough of dabigatran at approximately 70 ng/mL was estimated.",Dosage Adjustment of Dabigatran Etexilate Based on Creatinine Clearance in Patients With Cardioembolic Stroke or Atrial Fibrillation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27559839/),[ng] / [ml],70,260196,DB06695,Dabigatran etexilate
,27559839,Ctrough,"Depending on CLxr of patients, we recommend 4 different dosages of dabigatran etexilate to obtain Ctrough of dabigatran at approximately 70 ng/mL.",Dosage Adjustment of Dabigatran Etexilate Based on Creatinine Clearance in Patients With Cardioembolic Stroke or Atrial Fibrillation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27559839/),[ng] / [ml],70,260197,DB06695,Dabigatran etexilate
,34256392,concentration,Median concentration on admission was 205 ng/mL for rivaroxaban and 108 ng/mL for apixaban.,Pharmacokinetics of Direct Oral Anticoagulants in Emergency Situations: Results of the Prospective Observational RADOA-Registry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34256392/),[ng] / [ml],205,269424,DB06695,Dabigatran etexilate
,34256392,concentration,Median concentration on admission was 205 ng/mL for rivaroxaban and 108 ng/mL for apixaban.,Pharmacokinetics of Direct Oral Anticoagulants in Emergency Situations: Results of the Prospective Observational RADOA-Registry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34256392/),[ng] / [ml],108,269425,DB06695,Dabigatran etexilate
,34256392,t ½,"In rivaroxaban-treated patients t ½ was 17.3 hours (95% confidence interval [CI]: 15.4-19.7) without significant difference in both groups (major bleeding: t ½ 16.7 hours, 95% CI: 14.7-19.3; urgent surgery: t ½ 19.7 hours, 95% CI: 15.2-27.9; p = 0.292).",Pharmacokinetics of Direct Oral Anticoagulants in Emergency Situations: Results of the Prospective Observational RADOA-Registry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34256392/),h,17.3,269426,DB06695,Dabigatran etexilate
,34256392,t ½,"In rivaroxaban-treated patients t ½ was 17.3 hours (95% confidence interval [CI]: 15.4-19.7) without significant difference in both groups (major bleeding: t ½ 16.7 hours, 95% CI: 14.7-19.3; urgent surgery: t ½ 19.7 hours, 95% CI: 15.2-27.9; p = 0.292).",Pharmacokinetics of Direct Oral Anticoagulants in Emergency Situations: Results of the Prospective Observational RADOA-Registry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34256392/),h,16.7,269427,DB06695,Dabigatran etexilate
,34256392,t ½,"In rivaroxaban-treated patients t ½ was 17.3 hours (95% confidence interval [CI]: 15.4-19.7) without significant difference in both groups (major bleeding: t ½ 16.7 hours, 95% CI: 14.7-19.3; urgent surgery: t ½ 19.7 hours, 95% CI: 15.2-27.9; p = 0.292).",Pharmacokinetics of Direct Oral Anticoagulants in Emergency Situations: Results of the Prospective Observational RADOA-Registry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34256392/),h,19.7,269428,DB06695,Dabigatran etexilate
,34256392,t ½,In apixaban-treated patients t ½ was 25.0 hours (95% CI: 22.9-27.6) with a longer t ½ after urgent surgery (t 1/2: 30.8 hours; 95% CI: 26.9-36.4) compared with severe bleeding (t 1/2: 20.8 hours; 95% CI: 18.8-23.2; p < 0.001).,Pharmacokinetics of Direct Oral Anticoagulants in Emergency Situations: Results of the Prospective Observational RADOA-Registry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34256392/),h,25.0,269429,DB06695,Dabigatran etexilate
,34256392,t 1/2,In apixaban-treated patients t ½ was 25.0 hours (95% CI: 22.9-27.6) with a longer t ½ after urgent surgery (t 1/2: 30.8 hours; 95% CI: 26.9-36.4) compared with severe bleeding (t 1/2: 20.8 hours; 95% CI: 18.8-23.2; p < 0.001).,Pharmacokinetics of Direct Oral Anticoagulants in Emergency Situations: Results of the Prospective Observational RADOA-Registry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34256392/),h,30.8,269430,DB06695,Dabigatran etexilate
,34256392,t 1/2,In apixaban-treated patients t ½ was 25.0 hours (95% CI: 22.9-27.6) with a longer t ½ after urgent surgery (t 1/2: 30.8 hours; 95% CI: 26.9-36.4) compared with severe bleeding (t 1/2: 20.8 hours; 95% CI: 18.8-23.2; p < 0.001).,Pharmacokinetics of Direct Oral Anticoagulants in Emergency Situations: Results of the Prospective Observational RADOA-Registry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34256392/),h,20.8,269431,DB06695,Dabigatran etexilate
,18076218,t((1/2)),"With twice-daily administration of dabigatran etexilate, plasma concentrations of dabigatran reached steady state within 2-3 days, which is consistent with a t((1/2)) of 12-14 hours.",Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18076218/),h,12-14,270041,DB06695,Dabigatran etexilate
,18076218,peak plasma concentrations,"The mean (SD) peak plasma concentrations on day 4 of treatment in male and female elderly subjects were 256 ng/mL (21.8) and 255 ng/mL (84.0), respectively.",Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18076218/),[ng] / [ml],256,270042,DB06695,Dabigatran etexilate
,18076218,peak plasma concentrations,"The mean (SD) peak plasma concentrations on day 4 of treatment in male and female elderly subjects were 256 ng/mL (21.8) and 255 ng/mL (84.0), respectively.",Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18076218/),[ng] / [ml],255,270043,DB06695,Dabigatran etexilate
,25103614,trough level,The average dabigatran trough level was 69.3 ± 55.5 ng/ml and the average dabigatran peak level was 112.7 ± 66.6 ng/ml.,Monitoring of dabigatran therapy using Hemoclot(®) Thrombin Inhibitor assay in patients with atrial fibrillation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25103614/),[ng] / [ml],69.3,273242,DB06695,Dabigatran etexilate
,25103614,peak level,The average dabigatran trough level was 69.3 ± 55.5 ng/ml and the average dabigatran peak level was 112.7 ± 66.6 ng/ml.,Monitoring of dabigatran therapy using Hemoclot(®) Thrombin Inhibitor assay in patients with atrial fibrillation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25103614/),[ng] / [ml],112.7,273243,DB06695,Dabigatran etexilate
